"Cathepsins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of lysosomal proteinases or endopeptidases found in aqueous extracts of a variety of animal tissues. They function optimally within an acidic pH range. The cathepsins occur as a variety of enzyme subtypes including SERINE PROTEASES; ASPARTIC PROTEINASES; and CYSTEINE PROTEASES.
| Descriptor ID |
D002403
|
| MeSH Number(s) |
D08.811.277.656.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cathepsins".
Below are MeSH descriptors whose meaning is more specific than "Cathepsins".
This graph shows the total number of publications written about "Cathepsins" by people in this website by year, and whether "Cathepsins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cathepsins" by people in Profiles.
-
Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021 11 08; 6(1):379.
-
Halakos EG, Connell AJ, Glazewski L, Wei S, Mason RW. Bottom up proteomics identifies neuronal differentiation pathway networks activated by cathepsin inhibition treatment in neuroblastoma cells that are enhanced by concurrent 13-cis retinoic acid treatment. J Proteomics. 2021 02 10; 232:104068.
-
Smith BL, Gadd MA, Lanahan CR, Rai U, Tang R, Rice-Stitt T, Merrill AL, Strasfeld DB, Ferrer JM, Brachtel EF, Specht MC. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res Treat. 2018 Sep; 171(2):413-420.
-
Soori M, Lu G, Mason RW. Cathepsin Inhibition Prevents Autophagic Protein Turnover and Downregulates Insulin Growth Factor-1 Receptor-Mediated Signaling in Neuroblastoma. J Pharmacol Exp Ther. 2016 Feb; 356(2):375-86.
-
Harijith A, Choo-Wing R, Cataltepe S, Yasumatsu R, Aghai ZH, Jan?r J, Andersson S, Homer RJ, Bhandari V. A role for matrix metalloproteinase 9 in IFN?-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am J Respir Cell Mol Biol. 2011 May; 44(5):621-30.
-
Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA, Rebbaa A. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol. 2009 Jan; 296(1):C65-74.
-
Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, Brassard N, Prat A, Iozzo RV, Pshezhetsky AV, Hébert MJ. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem. 2008 Oct 3; 283(40):27220-9.
-
Rafiq K, Hanscom M, Valerie K, Steinberg SF, Sabri A. Novel mode for neutrophil protease cathepsin G-mediated signaling: membrane shedding of epidermal growth factor is required for cardiomyocyte anoikis. Circ Res. 2008 Jan 4; 102(1):32-41.
-
Hassanein M, Xue F, Seto CT, Mason RW. Development of a specific inhibitor for the placental protease, cathepsin P. Arch Biochem Biophys. 2007 Aug 15; 464(2):288-94.
-
Fain JN, Tichansky DS, Madan AK. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism. 2006 Aug; 55(8):1113-21.